Overview
This study is a multicentre, randomized, open-label, non-inferiority clinical trial.
The purpose and aim of this study is to investigate if patients with well controlled (UCT score score ≥ 12) chronic spontaneous urticaria (CSU) on omalizumab 300 mg every four weeks can extend treatment intervals and maintain disease control.
Description
Newly referred patients with CSU who are well-treated (UCT score ≥ 12) 12 weeks after initiating standard treatment with omalizumab 300 mg every four weeks, are randomized into two treatment arms.The first arm will continue standard treatment with omalizumab 300 mg every four weeks for 24 weeks. The second arm will receive treatment in an extended interval of omalizumab 300 mg every six weeks for 24 weeks.
Eligibility
Inclusion Criteria:
- Diagnosis of CSU according to the EAACI/GA2LEN/EDF/WAO guidelines
- Age ≥ 18 years
- Urticaria Control Test (UCT) score ≥ 12 at week 12 after initiating treatment with 300 mg of omalizumab every four weeks.
- Omalizumab-naïve prior to initiating treatment.
- Background treatment with four antihistamines daily.
- Type I CSU (negative basophil histamine release assay - BHRA).
- Identified as a candidate for omalizumab treatment according to Danish practice.
Exclusion Criteria:
- Pregnant or breastfeeding women
- Planned pregnancy within the next 6 months.
- Weight ≥ 100 kilograms
- Presence of any other active skin disease or condition that may interfere with the assessment of CSU, such as atopic dermatitis, bullous pemphigoid, senile pruritus, or psoriasis.
- Use of immunosuppressive drugs, such as prednisolone, azathioprine, methotrexate, or cyclosporine.
- Predominantly experiencing symptoms from chronic inducible urticaria (CIndU).
- Positive basophil histamine release assay (BHRA).
- Inability to complete the study or comply with study procedures.